Camptothecin delivery systems: The utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs

Anti-Cancer Drug Design

Volumn 14, Issue 6, 1999, Pages 499-506

  Conover, Charles D ^a   Greenwald, Richard B ^a   Pendri, Annapurna ^a   Shum, Kwok L ^a  

^a Enzon Incorporated   (United States)

Author keywords

Camptothecin; Mouse; Polyethylene glyco; Prodrug; Xenograft

Indexed keywords

ALANINE; AMINO ACID; CAMPTOTHECIN; MACROGOL; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; BREAST CANCER; COLON CANCER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG SCREENING; DRUG STABILITY; DRUG TOXICITY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA P 388; LUNG CANCER; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PLASMA; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HYDROLYSIS; LEUKEMIA P388; MICE; MICE, INBRED ICR; NEOPLASMS, EXPERIMENTAL; POLYETHYLENE GLYCOLS; PRODRUGS; RATS; SOLVENTS; TUMOR CELLS, CULTURED;

ANIMALIA; MURINAE;

EID: 0033512145     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Adamovics J.A., Hutchinson C.R. (1979) Prodrug analogues of the antitumor alkaloid camptothecin. Journal of Medicinal Chemistry, 22, 310.
2. Balimane P.V., Tamai I., Guo A., Nakanishi T., Kitada H., Leibach F.H., Tsuji A., Sinko P.J. (1998) Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochemical and Biophysical Research Communications, 250, 246.
3. Baurain R., Masquelier M., Deprez-De Campeneere D., Trouet A. (1980) Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on 11210 leukemic cells in vitro and in vivo. Journal of Medicinal Chemistry, 23, 1171.
4. Burke T., Mi Z. (1993) Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. Journal of Medicinal Chemistry, 36, 2580.
5. Cao Z., Harris N., Kozielski A., Vardeman D., Stehlin S., Giovanella B. (1998) Alkyl esters of camptothecin and 9-nitrocampthothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. Journal of Medicinal Chemistry, 41, 31.
6. Carl P., Chakravarty P., Katzenellenbogen J. (1981) A novel connector linkage applicable in prodrug design. Journal of Medicinal Chemistry, 24, 479.
7. Conover C.D., Pendri A., Lee C., Gilbert C.W., Shum K.L., Greenwald R.B. (1997) Camptothecin delivery systems: the antitumor activity of a camptothecin-20-polyethylene glycol ester transport form. Anticancer Research, 117, 3361.
8. Conover C.D., Greenwald R.B., Pendri A., Gilbert C.W., Shum K.L. (1998) Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemotherapy Pharmacology, 42, 407.
9. Corbett T., Valeriote F., Polin L., Panchapor C., Pygh S., White K., Lowichik N., Knight J., Bissery M., Wizniak A., Lorusso P., Biernat L., Polin D., Knight L., Biggar S., Looney D., Demchik L., Jones J., Jones L., Blair S., Palmer K., Essenmacher S., Lisow L., Mattles K., Cavanaugh P., Rake J., Baker L. (1992) Discovery of solid tumor active agents using a soft-agar-colony formation disk-diffusion-assay. In Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. Valeriote F., Corbett T., Baker L. (eds), p. 77. Kluwer: Boston, MA.
10. Duncan R. (1992) Drug - polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs, 3, 175.
11. Francis G.E., Delgado C., Fisher D., Malik F., Agrawal A.K. (1996) Polyethylene glycol modification: relevance of improved methodology to tumour targeting. Journal of Drug Targeting, 3, 321.
12. Giovanella B., Hinz H., Kozielski A., Stehlin J., Silber R., Potmesil M. (1991) Complete growth inhibition of human cancer xenograft in nude mice by treatment with 20-(S)-camptothecin. Cancer Research, 51, 3052.
13. Greenwald R. (1997) Drug delivery systems: anticancer prodrugs and their polymeric conjugates. Expert Opinion on Therapeutic Patents, 7, 601.
14. Greenwald R., Pendri A., Conover C., Gilbert C., Yang R., Xia J. (1996a) Drug delivery systems. 2. Camptothecin-20-O-poly(ethylene glycol) ester transport forms. Journal of Medicinal Chemistry, 39, 1938.
15. Greenwald R.B., Gilbert C.W., Pendri A., Xia J., Martinez A. (1996b) Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs - design and in vivo effectiveness. Journal of Medicinal Chemistry, 39, 424.
16. Greenwald R.B., Pendri A., Conover C.D., Lee C., Choe Y.H., Gilbert C., Martinez A., Xia, J., Wu D., Hsue M. (1998) Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. Bioorganic and Medicinal Chemistry, 6, 551.
17. Greenwald R.B., Conover C.D., Pendri A., Choe Y.H., Martinez A., Wu D., Guan S., Yao Z., Shum K.L. (1999) Drug delivery of anticancer drugs: water soluble 4-poly-(ethylene glycol) derivatives of the lignan, podophyllotoxin. Journal of Controlled Release, 61, 281.
18. Han H., Oh D., Amidon G.L. (1998) Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/ hPEPT1 cells overexpressing a human peptide transporter. Pharmaceutical Research, 15, 1382.
19. Hess R. (1960) Localization of a cathepsin-like and aminopeptidase activity in various solid tumor transplants. Cancer Research, 20, 940.
20. Keppler D., Fondanoche M.C., Dalet-Fumeron V., Pagano M., Burtin P. (1988) Immunohistochemical and biochemical study of a cathepsin B-like proteinase in human colonic cancers. Cancer Research, 48, 6855.
21. Kingsbury W., Boehm J., Jakas D., Holden K., Hecht S., Gallagher G., Caranfa M., McCabe F., Faucette L., Johnson R., Hertzberg R. (1991) Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. Journal of Medicinal Chemistry, 34, 98.
22. Maeda H., Seymour L., Miyamoto Y. (1992) Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chemistry, 3, 351.
23. Murakami Y., Tabata Y., Ikada Y. (1997) Tumor accumulation of poly(ethylene glycol) with different molecular weights after intravenous injection. Drug Delivery, 4, 23.
24. Noguchi Y., Wun J., Duncan R., Strohalm J., Ulbrich K., Akaike T., Maeda H. (1998) Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Japanese Journal of Cancer Research, 89, 307.
25. Pendri A., Conover C.D., Greenwald R.B. (1998) Antitumor activity of paclitaxel-2′-glycinate conjugated to poly-(ethylene glycol): a water soluble prodrug. Anti-Cancer Drug Design, 13, 387.
26. Rao Vishnuvajjala B., Garzon-Aburbeh A. (1990) Water soluble prodrugs of camptothecin. US Patent 4,943,579.
27. Recklies A.D., Tiltman K.J., Stoker A.M., Poole A.R. (1980) Secretion of proteinases from malignant and nonmalignant human breast tissue. Cancer Research, 40, 550.
28. Rivory L., Robert J. (1995) Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmaceutical Therapeutics, 68, 269.
29. Soyez H., Schacht E., Vanderkerken S. (1996) The crucial role of spacer groups in macromolecular prodrug design. Advanced Drug Delivery Review, 21, 81.
30. Takakura Y., Hashida M. (1995) Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Critical Reviews in Oncology/Hematology, 18, 207.
31. Wall M., Wani M. (1977) Antineoplastic agents from plants. Annual Review of Pharmacology and Toxicology, 17, 117.
32. Wall M., Wani M. (1995) Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Research, 55, 753.